Myriad Genetics Inc

MYGN is in a Stage 2 advancing regime with a clear sequence of higher highs and higher lows supported by rising EMAs and bullish continuation patterns; however, price is extremely overbought and extended above the EMAs near the declining 200-day SMA, so execution is deferred until a pullback into the rising short-term EMAs and consolidation resolution offers a better entry.

• ↑MyRisk hereditary cancer tests grew 10% YoY, boosting oncology revenues
• ↑Invested $35M in commercial capabilities to sharpen execution and drive growth
• ↓Lowered 2026 revenue outlook to $770M–790M, down ~$90M due to prenatal volume declines